Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (405)	6/3/1999 10:25:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 3158

Seems like a logical move on Roche's part - exercise their option and sell part of it back. Good for biotech, I think, for GNE to remain visible rather than get totally submerged into a pharma. Be a bunch of money ($3 billion)floating around for a while waiting to re-enter Genentech. URL: cbs.marketwatch.com Roche will buy rest of Genentech Decision follows jury deadlock in U.C. patent case By Tom Murphy and Suzanne Miller, CBS MarketWatch Last Update: 7:01 AM ET Jun 3, 1999 Discussion group Legal Options ZURICH (CBS.MW) -- Roche AG said Thursday it will buy the third of Genentech Corp. it doesn't already own, then sell up to 19 percent of its stock back to the public so the biotech company can remain independent.